Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.
about
Severe osteomyelitis caused by Myceliophthora thermophila after a pitchfork injuryAntifungal therapy in infants and children with proven, probable or suspected invasive fungal infectionsAntifungal therapy in infants and children with proven, probable or suspected invasive fungal infectionsTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectivePharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsPopulation pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3Voriconazole pharmacokinetics and pharmacodynamics in children.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerSafety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theClinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.Management of neonatal candidiasis. Neonatal Candidiasis Study GroupMicafungin in the treatment of invasive candidiasis and invasive aspergillosisPharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus.Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications.Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.Diagnostic and therapeutic challenges in a liver transplant recipient with central nervous system invasive aspergillosis.Pharmacokinetics of antifungal agents in children.Voriconazole: review of a broad spectrum triazole antifungal agent.Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.A review of clinical experience with newer antifungals in childrenTriazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazoleTherapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome.The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.
P2860
Q21245798-EA615C31-5A72-4048-834B-47B9FDB8E2D1Q24239978-3FF38239-6ECE-44C0-8B5B-E97C093629BAQ24243629-37680C19-3612-4038-9817-F02871911DC8Q27009221-15E339B3-A4E5-47CE-B75D-A18E695AB92DQ27025299-7113DB19-1A16-4CC8-AFCA-CF5269C2149AQ33392206-A3DBE809-4909-4FD1-A0A6-CAC93F406090Q33574651-CD2BFED9-7E31-4BA0-B629-AE046E08A310Q33577291-8E4CBAD7-FE93-404B-99E5-0AFE7FBE99EAQ33650105-2C0FCAC2-381D-4310-9157-34794D4B4612Q33938201-21CE67E7-3B2B-41AA-A9DA-A0A5FB66E918Q34045383-7434FD99-DAF1-4E54-8FBE-0622E2267EB2Q34138276-8AB47F15-5CD4-400B-BCB2-F30991D8AA57Q34150923-7A88CCF0-E842-4C65-9F3D-683C5982C92FQ34150943-6C8982F8-7A71-403C-8BDA-1A6F0721093DQ34212799-A8D0AF1B-137E-4BCC-8751-FBF7F72A10ACQ34505582-56E1BA64-DDF8-4D9E-B24C-04BBD598DE7EQ34532546-96A3E74B-22DF-4368-AAE2-309C9FB21761Q34596313-5FD335A0-B4CD-456D-A7D1-A67C84C965DCQ34680771-E8C1D736-F509-43D8-B8F2-6BFF1E89CB99Q35026516-3DE5FB69-F214-44F6-8A35-05772FF789F7Q35105949-1DF4DEBB-8BCF-479B-A1F2-F65C765012D3Q35270270-5EDAAE9F-18C1-4F8D-A820-42D21978B2E1Q35598464-B01B2E2B-25BE-4DAD-8D6A-22435980D246Q35598532-0E3AC582-C567-49B2-A152-E57BEAB3D9ACQ35635830-4F21A5B6-2360-40C2-BE5A-3073E930A366Q35647678-EA391016-42BF-46F7-A8C2-E181CD9F9DE5Q35647730-30BFAD59-7973-4078-AC58-C61B62AF68BAQ35889014-AF26A486-F68A-430A-8E6B-CFD97AD53806Q35912756-842D843F-B4A4-4DB4-9FEA-F9EFB2820A68Q35973543-CB7070D9-E1C4-49D1-A55A-6CACF1D85850Q36018595-0705BC67-E6A0-4E96-A019-0769BEB4AC05Q36094956-295A251C-883B-4A46-ABF8-CDAA8214F2C9Q36163345-89EAE3CD-C336-4707-AF1D-6F0DF2B901EBQ36164008-ED9777DD-9CD3-4461-AAC8-3FCC0FA262C6Q36271648-1548C8C9-D784-4A0F-B4ED-05BCBCD1E0B6Q36290698-E1DE8151-33A1-47EF-95E8-B52B5328AEF6Q36521993-38AF1033-7832-43A7-9D58-FD8C2A49A6A1Q36608562-E2AAFC69-C0DC-4C95-85D5-CCD1177B7E81Q36822025-C9FF1FF1-B9A3-4746-A9E5-D072CBC77E71Q36828156-E4AB9BE6-8320-44F2-B675-7281714235EC
P2860
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Pharmacokinetics and safety of ...... multiple-dose administration.
@ast
Pharmacokinetics and safety of ...... multiple-dose administration.
@en
Pharmacokinetics and safety of ...... multiple-dose administration.
@nl
type
label
Pharmacokinetics and safety of ...... multiple-dose administration.
@ast
Pharmacokinetics and safety of ...... multiple-dose administration.
@en
Pharmacokinetics and safety of ...... multiple-dose administration.
@nl
prefLabel
Pharmacokinetics and safety of ...... multiple-dose administration.
@ast
Pharmacokinetics and safety of ...... multiple-dose administration.
@en
Pharmacokinetics and safety of ...... multiple-dose administration.
@nl
P2093
P2860
P1476
Pharmacokinetics and safety of ...... multiple-dose administration.
@en
P2093
Adriano G Arguedas
Ajay J Vora
Antonio C Arrieta
Jeffrey Blumer
Mats O Karlsson
Nolan Wood
Peter Adamson
Peter Milligan
Thomas J Walsh
Timothy Driscoll
P2860
P304
P356
10.1128/AAC.48.6.2166-2172.2004
P407
P50
P577
2004-06-01T00:00:00Z